DK1146908T3 - Formuleringer omfattende antisense-nukleotider mod connexiner - Google Patents

Formuleringer omfattende antisense-nukleotider mod connexiner

Info

Publication number
DK1146908T3
DK1146908T3 DK00901236T DK00901236T DK1146908T3 DK 1146908 T3 DK1146908 T3 DK 1146908T3 DK 00901236 T DK00901236 T DK 00901236T DK 00901236 T DK00901236 T DK 00901236T DK 1146908 T3 DK1146908 T3 DK 1146908T3
Authority
DK
Denmark
Prior art keywords
formulations
antisense nucleotides
reduction
nucleotides against
connexin
Prior art date
Application number
DK00901236T
Other languages
Danish (da)
English (en)
Inventor
David Laurence Becker
Colin Richard Green
Original Assignee
Becker David Dr
Green Colin R Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Becker David Dr, Green Colin R Dr filed Critical Becker David Dr
Application granted granted Critical
Publication of DK1146908T3 publication Critical patent/DK1146908T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
DK00901236T 1999-01-27 2000-01-27 Formuleringer omfattende antisense-nukleotider mod connexiner DK1146908T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ33392899 1999-01-27
NZ50019099 1999-10-07
PCT/GB2000/000238 WO2000044409A1 (en) 1999-01-27 2000-01-27 Formulations comprising antisense nucleotides to connexins

Publications (1)

Publication Number Publication Date
DK1146908T3 true DK1146908T3 (da) 2005-10-10

Family

ID=26652011

Family Applications (3)

Application Number Title Priority Date Filing Date
DK00901236T DK1146908T3 (da) 1999-01-27 2000-01-27 Formuleringer omfattende antisense-nukleotider mod connexiner
DK10013180.4T DK2314321T3 (da) 1999-01-27 2000-01-27 Formuleringer, der omfatter antisense-nukleotider til connexiner
DK05016736.0T DK1621212T3 (da) 1999-01-27 2000-01-27 Formuleringer omfattende antisense-nukleotider til connexiner

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK10013180.4T DK2314321T3 (da) 1999-01-27 2000-01-27 Formuleringer, der omfatter antisense-nukleotider til connexiner
DK05016736.0T DK1621212T3 (da) 1999-01-27 2000-01-27 Formuleringer omfattende antisense-nukleotider til connexiner

Country Status (13)

Country Link
US (11) US7098190B1 (https=)
EP (3) EP1146908B1 (https=)
JP (4) JP4994533B2 (https=)
AT (2) ATE300959T1 (https=)
AU (1) AU776512B2 (https=)
CA (2) CA2361251C (https=)
CY (2) CY1112557T1 (https=)
DE (1) DE60021700T2 (https=)
DK (3) DK1146908T3 (https=)
ES (3) ES2498745T3 (https=)
NZ (1) NZ513154A (https=)
PT (3) PT1621212E (https=)
WO (1) WO2000044409A1 (https=)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5991308A (ja) * 1982-11-16 1984-05-26 Kawasaki Heavy Ind Ltd 平面の検出方法
DK1146908T3 (da) 1999-01-27 2005-10-10 Becker David Dr Formuleringer omfattende antisense-nukleotider mod connexiner
EP1197553A1 (en) * 2000-10-12 2002-04-17 A3D GmbH, Antisense Design & Drug Development Antisense nucleic acid against alphaV integrin
US20050119211A1 (en) * 2001-05-18 2005-06-02 Sirna Therapeutics, Inc. RNA mediated inhibition connexin gene expression using short interfering nucleic acid (siNA)
CA3059497A1 (en) * 2003-12-03 2005-06-16 Ocunexus Therapeutics, Inc. Antisense compounds targeted to connexins and methods of use thereof
US9408381B2 (en) 2004-12-21 2016-08-09 Musc Foundation For Research Development Alpha Connexin c-Terminal (ACT) peptides for use in transplant
SG158153A1 (en) 2004-12-21 2010-01-29 Musc Found For Res Dev Compositions and methods for promoting wound healing and tissue regeneration
DK1959981T3 (da) 2005-02-03 2020-01-27 Coda Therapeutics Ltd Anti-connexin 43 forbindelser til behandling af kroniske sår
WO2007055224A1 (ja) * 2005-11-08 2007-05-18 Kansai Technology Licensing Organization Co., Ltd. 角膜疾患治療剤
JP5713377B2 (ja) 2005-12-28 2015-05-07 ザ スクリプス リサーチ インスティテュート 薬物標的としての天然アンチセンスおよび非コードｒｎａ転写物
JP2010507387A (ja) 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド 新規のｓｉＲＮＡおよびその使用方法
EP2091557A2 (en) * 2006-11-15 2009-08-26 Coda Therapeutics, INC. Improved methods and compositions for wound healing
AU2014204482B2 (en) * 2006-12-11 2016-07-07 Coda Therapeutics, Inc. Anticonnexin polynucleotides as impaired wound healing compositions
CN101835476B (zh) 2006-12-11 2016-08-17 科达治疗公司 作为受损伤口愈合组合物的抗连接蛋白多核苷酸
DK2166845T3 (en) * 2007-06-21 2016-02-01 Musc Found For Res Dev ALFA-connexin C-terminal (ACT) peptides FOR THE TREATMENT OF AGE-related macular degeneration
RU2487716C2 (ru) 2007-10-03 2013-07-20 Кварк Фармасьютикалс, Инк. Новые структуры малых интерферирующих рнк (sirna)
EP2245158A2 (en) * 2007-12-11 2010-11-03 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
US20110300130A1 (en) 2007-12-11 2011-12-08 Becker David L Impaired wound healing compositions and treatments
CA2710232A1 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Treatment of abnormal or excessive scars
JP2011507861A (ja) * 2007-12-21 2011-03-10 コーダ セラピューティクス， インコーポレイテッド 線維症性の状態の治療のための抗コネキシンポリヌクレオチド剤と組み合わせた抗コネキシンポリペプチド剤の使用
US8975237B2 (en) * 2007-12-21 2015-03-10 Coda Therapeutics, Inc. Treatment of fibrotic conditions
US20110144182A1 (en) * 2007-12-21 2011-06-16 David Lawrence Becker Treatment of surgical adhesions
CA2710375A1 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Treatment of orthopedic conditions
JP2011507599A (ja) 2007-12-21 2011-03-10 コーダ セラピューティクス， インコーポレイテッド 改良医療デバイス
US20110243964A1 (en) * 2007-12-21 2011-10-06 Bradford James Duft Treatment of orthopedic conditions
AU2008343758A1 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin 43 polynucleotides for the treatment of abnormal or excessive scars
AU2008343839A1 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin peptides, alone or in combination with anti-connexin polynucleotides, for the treatment of surgical adhesions
US20110038920A1 (en) * 2008-01-07 2011-02-17 Ryoichi Mori Wound healing compositions and treatments
EP2342340A1 (en) 2008-09-22 2011-07-13 Rxi Pharmaceuticals Corporation Rna interference in skin indications
CN102239260B (zh) 2008-10-03 2017-04-12 库尔纳公司 通过抑制针对载脂蛋白‑a1的天然反义转录物治疗载脂蛋白‑a1相关疾病
US20110294870A1 (en) 2008-12-04 2011-12-01 Opko Curna, Llc Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
ES2600781T3 (es) 2008-12-04 2017-02-10 Curna, Inc. Tratamiento para enfermedades relacionadas con el factor de crecimiento del endotelio vascular (vegf) mediante la inhibición de transcritos antisentido naturales de vegf
ES2629630T3 (es) 2008-12-04 2017-08-11 Curna, Inc. Tratamiento de enfermedades relacionadas con eritropoyetina (EPO) mediante inhibición del transcrito antisentido natural a EPO
US8669941B2 (en) * 2009-01-05 2014-03-11 Nuance Communications, Inc. Method and apparatus for text entry
ES2762610T3 (es) 2009-02-12 2020-05-25 Curna Inc Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado de cerebro (BDNF) por inhibición de transcrito antisentido natural para BDNF
CN102482677B (zh) 2009-03-16 2017-10-17 库尔纳公司 通过抑制nrf2的天然反义转录物治疗核因子(红细胞衍生2)‑样2(nrf2)相关疾病
WO2010107740A2 (en) 2009-03-17 2010-09-23 Curna, Inc. Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
CN103223177B (zh) 2009-05-06 2016-08-10 库尔纳公司 通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
ES2609655T3 (es) 2009-05-06 2017-04-21 Curna, Inc. Tratamiento de enfermedades relacionadas con tristetraprolina (TTP) mediante inhibición de transcrito antisentido natural para TTP
JP5931720B2 (ja) 2009-05-08 2016-06-08 クルナ・インコーポレーテッド Ｄｍｄファミリーに対する天然アンチセンス転写物の抑制によるジストロフィンファミリー関連疾患の治療
DK2432881T3 (en) 2009-05-18 2018-02-26 Curna Inc TREATMENT OF REPROGRAMMING FACTOR-RELATED DISEASES BY INHIBITING NATURAL ANTISENSE TRANSCRIPTS TO A REPROGRAMMING FACTOR
CA2762987A1 (en) 2009-05-22 2010-11-25 Joseph Collard Treatment of transcription factor e3 (tfe3) and insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to tfe3
KR101704988B1 (ko) 2009-05-28 2017-02-08 큐알엔에이, 인크. 항바이러스 유전자에 대한 천연 안티센스 전사체의 억제에 의한 항바이러스 유전자 관련된 질환의 치료
WO2010148050A2 (en) 2009-06-16 2010-12-23 Curna, Inc. Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
US8951981B2 (en) 2009-06-16 2015-02-10 Curna, Inc. Treatment of paraoxonase 1 (PON1) related diseases by inhibition of natural antisense transcript to PON1
WO2010151671A2 (en) 2009-06-24 2010-12-29 Curna, Inc. Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
EP2446037B1 (en) 2009-06-26 2016-04-20 CuRNA, Inc. Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
CN102712925B (zh) 2009-07-24 2017-10-27 库尔纳公司 通过抑制sirtuin(sirt)的天然反义转录物来治疗sirtuin(sirt)相关性疾病
CN102762731B (zh) 2009-08-05 2018-06-22 库尔纳公司 通过抑制针对胰岛素基因(ins)的天然反义转录物来治疗胰岛素基因(ins)相关的疾病
CN104313027B (zh) 2009-08-11 2018-11-20 库尔纳公司 通过抑制脂连蛋白(adipoq)的天然反义转录物治疗脂连蛋白(adipoq)相关疾病
KR101805213B1 (ko) 2009-08-21 2017-12-06 큐알엔에이, 인크. Ｃｈｉｐ에 대한 천연 안티센스 전사체의 억제에 의한 “ｈｓｐ70-상호작용 단백질(ｃｈｉｐ)의 ｃ-말단” 관련된 질환의 치료
CA2771172C (en) 2009-08-25 2021-11-30 Opko Curna, Llc Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
US20120295952A1 (en) 2009-09-25 2012-11-22 Curna, Inc. Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
JP6025567B2 (ja) 2009-12-16 2016-11-16 カッパーアールエヌエー，インコーポレイテッド 膜結合転写因子ペプチダーゼ、部位１（ｍｂｔｐｓ１）に対する天然アンチセンス転写物の阻害によるｍｂｔｐｓ１関連性疾患の治療
RU2619185C2 (ru) 2009-12-23 2017-05-12 Курна, Инк. Лечение заболеваний, связанных с разобщающим белком 2 (ucp2), путем ингибирования природного антисмыслового транскрипта к ucp2
CN102869776B (zh) 2009-12-23 2017-06-23 库尔纳公司 通过抑制肝细胞生长因子(hgf)的天然反义转录物而治疗hgf相关疾病
EP2519633B1 (en) 2009-12-29 2017-10-25 CuRNA, Inc. Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
ES2585829T3 (es) 2009-12-29 2016-10-10 Curna, Inc. Tratamiento de las enfermedades relacionadas con la proteína tumoral 63 (p63) por inhibición de transcripción antisentido natural a p63
CA2785727C (en) 2009-12-31 2020-01-07 Curna, Inc. Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3)
CA2785832A1 (en) 2010-01-04 2011-07-07 Curna, Inc. Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8
KR101853509B1 (ko) 2010-01-06 2018-04-30 큐알엔에이, 인크. 췌장 발달 유전자에 대한 천연 안티센스 전사체의 억제에 의한 췌장 발달 유전자와 관련된 질환의 치료
JP6027893B2 (ja) 2010-01-11 2016-11-16 カッパーアールエヌエー，インコーポレイテッド 性ホルモン結合グロブリン（ｓｈｂｇ）に対する天然アンチセンス転写物の阻害による性ホルモン結合グロブリン（ｓｈｂｇ）関連疾患の治療
EP2529015B1 (en) 2010-01-25 2017-11-15 CuRNA, Inc. Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1
CN102844435B (zh) 2010-02-22 2017-05-10 库尔纳公司 通过抑制吡咯啉‑5‑羧酸还原酶1(pycr1)的天然反义转录物而治疗pycr1相关疾病
EP3560503B1 (en) 2010-03-24 2021-11-17 Phio Pharmaceuticals Corp. Rna interference in dermal and fibrotic indications
RU2612884C2 (ru) 2010-04-02 2017-03-13 Курна, Инк. Лечение заболеваний, связанных с колониестимулирующим фактором 3 (csf3), путем ингибирования природного антисмыслового транскрипта k csf3
WO2011127337A2 (en) 2010-04-09 2011-10-13 Opko Curna Llc Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
WO2011139387A1 (en) 2010-05-03 2011-11-10 Opko Curna, Llc Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
TWI531370B (zh) 2010-05-14 2016-05-01 可娜公司 藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
US8895528B2 (en) 2010-05-26 2014-11-25 Curna, Inc. Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
ES2664585T3 (es) 2010-05-26 2018-04-20 Curna, Inc. Tratamiento de enfermedades relacionadas con metionina sulfóxido reductasa (MSRA) mediante inhibición del transcrito antisentido natural a MSRA
CN109112126B (zh) 2010-06-23 2024-06-14 库尔纳公司 通过抑制电压门控钠通道α亚基(SCNA)的天然反义转录物而治疗SCNA相关疾病
JP5998131B2 (ja) 2010-07-14 2016-09-28 カッパーアールエヌエー，インコーポレイテッド Ｄｉｓｃｓｌａｒｇｅｈｏｍｏｌｏｇ（ｄｌｇ）ｄｌｇ１への天然アンチセンス転写物の阻害によるｄｌｇ関連疾患の治療
CN103210086B (zh) 2010-10-06 2017-06-09 库尔纳公司 通过抑制唾液酸酶4(neu4)的天然反义转录物而治疗neu4相关疾病
KR101865433B1 (ko) 2010-10-22 2018-07-13 큐알엔에이, 인크. 알파-l 이두로니다아제 (idua)에 대한 자연 안티센스 전사체의 저해에 의한 idua 관련된 질환의 치료
US10000752B2 (en) 2010-11-18 2018-06-19 Curna, Inc. Antagonat compositions and methods of use
WO2012071238A2 (en) 2010-11-23 2012-05-31 Opko Curna Llc Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog
KR102043422B1 (ko) 2011-06-09 2019-11-11 큐알엔에이, 인크. 프라탁신 (fxn)에 대한 자연 안티센스 전사체의 저해에 의한 프라탁신 (fxn) 관련된 질환의 치료
MX365525B (es) 2011-09-06 2019-06-06 Curna Inc Compuestos que regulan la expresión de subunidades alfa de canales de sodio regulados por voltaje en enfermedades relacionadas con epilepsia mioclónica severa de la infancia.
US9308163B2 (en) 2012-02-15 2016-04-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of treating and preventing diseases and disorders of the central nervous system
CA2866115C (en) 2012-03-01 2020-03-24 Firststring Research, Inc. Topical gels containing alpha connexin c-terminal (act) peptides
HK1210211A1 (en) 2012-03-15 2016-04-15 科纳公司 Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
CA2868534A1 (en) 2012-03-27 2013-10-03 Coda Therapeutics, Inc. Compositions and treatments based on cadherin modulation
US20140274872A1 (en) * 2013-03-15 2014-09-18 Coda Therapeutics, Inc. Compositions and treatments based on cadherin modulation
WO2014164805A1 (en) * 2013-03-11 2014-10-09 University Of North Carolina At Chapel Hill Compositions and methods for targeting o-linked n-acetylglucosamine transferase and promoting wound healing
US9156896B2 (en) 2013-03-15 2015-10-13 Coda Therapeutics, Inc. Wound healing compositions and treatments
CN105960265A (zh) * 2013-12-04 2016-09-21 阿克赛医药公司 利用经化学修饰的寡核苷酸处理伤口愈合的方法
WO2015130840A2 (en) * 2014-02-25 2015-09-03 Coda Therapeutics, Inc. Treatment of resistant lesions
WO2015191795A1 (en) 2014-06-12 2015-12-17 The Research Foundation For The State University Of New York Methods of using gap junctions as therapeutic targets for the treatment of degenerative disorders of the retina
US10465188B2 (en) 2014-08-22 2019-11-05 Auckland Uniservices Limited Channel modulators
US10900039B2 (en) 2014-09-05 2021-01-26 Phio Pharmaceuticals Corp. Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1
EP3419998A4 (en) * 2016-02-26 2019-09-25 The Board of Regents of The University of Texas System CONNEXIN (CX) 43 HEMICANAL BINDING ANTIBODIES AND USES THEREOF
US12544344B2 (en) * 2017-04-19 2026-02-10 Phio Pharmaceuticals Corp. Topical delivery of nucleic acid compounds
CN111201247A (zh) 2017-04-28 2020-05-26 奥克兰联合服务有限公司 治疗方法和新颖构建体
EP3685824A1 (en) * 2019-01-25 2020-07-29 Breitenbronn-Consulting GbR Composition for administering and releasing oligonucleotides
JP2023546757A (ja) 2020-10-22 2023-11-07 シークエル・バイオ・インコーポレイテッド ペプチド製剤および眼科におけるその使用
US20250289864A1 (en) * 2022-05-13 2025-09-18 University Of Utah Research Foundation Gja1-20k to limited cardiac arrhythmias

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9425930D0 (en) 1994-12-22 1995-02-22 Procter & Gamble Silicone compositions
JP2000504670A (ja) * 1996-01-31 2000-04-18 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 腫瘍細胞の成長を抑制する方法
EP1464703A3 (en) * 1996-03-07 2004-10-13 Eisai Co., Ltd. Canine adhesion molecule occludin
AU2458597A (en) * 1996-07-17 1998-02-09 Medtronic, Inc. System for genetically treating cardiac conduction disturbances
JP2001505432A (ja) * 1996-12-02 2001-04-24 ダイヤド ファーマシューティカル コーポレイション ヒト接着分子のアンチセンス阻害
EP1037981A1 (en) * 1997-12-09 2000-09-27 Children's Medical Center Corporation Soluble inhibitors of vascular endothelial growth factor and use thereof
DK1146908T3 (da) * 1999-01-27 2005-10-10 Becker David Dr Formuleringer omfattende antisense-nukleotider mod connexiner
US5998148A (en) * 1999-04-08 1999-12-07 Isis Pharmaceuticals Inc. Antisense modulation of microtubule-associated protein 4 expression

Also Published As

Publication number Publication date
US20080221051A1 (en) 2008-09-11
US7098190B1 (en) 2006-08-29
WO2000044409A1 (en) 2000-08-03
PT1621212E (pt) 2012-02-20
EP1146908A1 (en) 2001-10-24
AU776512B2 (en) 2004-09-09
ES2377749T3 (es) 2012-03-30
EP2314321A1 (en) 2011-04-27
EP1146908B1 (en) 2005-08-03
US9193754B2 (en) 2015-11-24
ATE300959T1 (de) 2005-08-15
US20070078103A1 (en) 2007-04-05
US20080249041A1 (en) 2008-10-09
JP5736397B2 (ja) 2015-06-17
JP2013135677A (ja) 2013-07-11
CY1112557T1 (el) 2016-02-10
JP5705890B2 (ja) 2015-04-22
US20070037765A1 (en) 2007-02-15
US20070066555A1 (en) 2007-03-22
DK1621212T3 (da) 2012-03-05
US7919474B2 (en) 2011-04-05
JP4994533B2 (ja) 2012-08-08
US7902164B2 (en) 2011-03-08
DK2314321T3 (da) 2014-09-08
NZ513154A (en) 2004-01-30
JP2012041342A (ja) 2012-03-01
DE60021700D1 (de) 2005-09-08
US7615540B2 (en) 2009-11-10
ATE533515T1 (de) 2011-12-15
US20130079388A1 (en) 2013-03-28
PT2314321E (pt) 2014-09-26
DE60021700T2 (de) 2006-06-01
JP2002535377A (ja) 2002-10-22
US8314074B2 (en) 2012-11-20
JP2013136594A (ja) 2013-07-11
CA2730386A1 (en) 2000-08-03
CA2361251C (en) 2011-03-08
CA2730386C (en) 2015-08-11
CA2361251A1 (en) 2000-08-03
US20110065770A1 (en) 2011-03-17
EP1621212B1 (en) 2011-11-16
EP2314321B1 (en) 2014-06-04
ES2245638T3 (es) 2006-01-16
US20070072820A1 (en) 2007-03-29
US7879811B2 (en) 2011-02-01
CY1115521T1 (el) 2017-01-04
AU2119300A (en) 2000-08-18
PT1146908E (pt) 2005-10-31
US20070060538A1 (en) 2007-03-15
ES2498745T3 (es) 2014-09-25
US20070072819A1 (en) 2007-03-29
EP1621212A1 (en) 2006-02-01

Similar Documents

Publication Publication Date Title
DK1146908T3 (da) Formuleringer omfattende antisense-nukleotider mod connexiner
EP2158907A3 (en) Topical administration of arginine for pain treatment
MY135988A (en) Additive for improving the water resistance of cosmetic or dermatological formulations
DE59911740D1 (de) Topisch anwendbare mittel gegen nagelpilzerkrankungen
CA2404810A1 (en) Topical composition having undifferentiated plant seed cells and method for using same
AU2001240940A1 (en) Cosmetic and dermatological composition for psoriatic skin, scalp treatment and care
ATE290397T1 (de) Formulierung fur die wundheilung mit menschlichem plasma fibronektin
JP2004500353A5 (https=)
PT1009425E (pt) Cicatrizacao de feridas
EP0471135B1 (en) Composition for the promotion of hair growth
BR0116293A (pt) Composição tópica, e, método para prevenir, melhorar ou tratar a hiperpigmentação da pele
ATE217514T1 (de) Verwendung von bradykininantagonisten zur induzierung oder stimulation des haarwachstums und/oder zur verlangsamung des haarausfalls
RU93002420A (ru) Способ лечения раны
IT1258069B (it) Composizione per uso topico avente attivita' di stimolo per la ricrescita, di rinvigorimento, di prevenzione dell'ingrigimento e di ripigmentazione naturale dei capelli
TW200501934A (en) Therapeutic causing contraction of mucosal tissue, method of treating diseases relating to mucosal tissues, injector and therapeutic set
IE810489L (en) Composition for topical application
GB9715085D0 (en) Gene therapy vehicle
WO1996001100A3 (de) Hydrogel für die applikation von therapeutischen und/oder kosmetischen wirkstoffen an die haut
AU3952300A (en) Method to reduce hair loss and stimulate hair regrowth
WO2000002601A3 (en) Transdermal delivery system
GB2368523A (en) Solid wound healing formulations containing fibronectin
WO2002030443A3 (en) Regulation of human skin healing
WO2002098515A3 (en) Topical treatments using alkanolamines
AU1564500A (en) Method for obtaining and using a combination of a purine and a nitrogen monoxidedonor for preventing or treating sexual dysfunction
AU6664598A (en) Use of curcumin in treatment of psoriasis, inflammation, skin wounds, burns, andeczemas